Core Insights - Recent breakthroughs in xenotransplantation using genetically modified pigs have garnered global attention, particularly in addressing the shortage of human organ donors [1][2] - The first successful transplantation of a genetically edited pig liver into a human recipient was reported in March 2024, demonstrating the potential for pig organs to serve as a transitional therapy for patients with liver failure [1][2] Group 1: Research Developments - In October 2021, NYU Langone Medical Center performed the first transplantation of a genetically edited pig kidney into a brain-dead woman [1] - In January 2022, the University of Maryland conducted the first live transplantation of a genetically edited pig heart, with the patient surviving for approximately two months [1] - A study published in Nature Medicine in July 2025 analyzed the immune cell landscape in a human recipient of a pig liver xenograft, highlighting the immune response post-transplantation [2][3] Group 2: Immune Response Analysis - The research utilized single-cell and spatial transcriptomics to characterize immune cell changes in the peripheral blood and transplanted liver of the human patient [3][7] - The study found that T cells in the peripheral blood were gradually activated, while γδT cells and exhausted T cells infiltrated the pig liver, indicating impaired adaptive immunity [8] - Two distinct monocyte subpopulations, THBS1+ and C1QC+, were identified, which may influence coagulation and immune responses post-xenotransplantation [9][11] Group 3: Implications for Future Research - The findings emphasize the role of innate immune cells in influencing coagulation and immune pathways following pig liver xenotransplantation, suggesting avenues for further research [11] - Understanding the roles of THBS1+ and C1QC+ monocytes could provide insights into early rejection responses and adaptive immune regulation in xenotransplantation [11]